StockData
Ligand Pharmaceuticals Inc logo

Ligand Pharmaceuticals Inc (LGND) stock

LGNDNasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as LGNDZ, LGNXZ, LGNYZ, LGNZZ
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 30, 2026Score 6/30433% above fair value
$298.71+4.90 (+1.67%)

Close on Nov 18, 2026Market cap $5.98BP/E 130.4Yield –

Ligand Pharmaceuticals pe ratio

The price-to-earnings ratio is the share price divided by diluted earnings per share over the trailing twelve months.

Ligand Pharmaceuticals's pe ratio was 33.7× on Nov 11, 2026, against 105.3× a year earlier. Over the last 5 years it ranged from 2.3× to 105.3×, with a median of 38.7×.

PE Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2026Nov 11, 202633.7×−64.3
2025Dec 31, 202598.0×+55.3
2024Dec 31, 202442.7×−48.9
2023Dec 29, 202391.6×+23.9
2022Jul 29, 202267.7×+29.0
2021Dec 31, 202138.7×+35.6
2020Apr 30, 20203.1×−0.7
2019Dec 31, 20193.8×−20.5
2018Dec 31, 201824.2×+6.6
2017Dec 29, 201717.6×−281.2
2016Dec 30, 2016298.9×+288.8
2015Dec 31, 201510.1×−156.2
2014Dec 31, 2014166.3×+63.1
2013Dec 31, 2013103.1×−193.1
2012Dec 31, 2012296.3×+272.1
2011Dec 30, 201124.2×–

More Ligand Pharmaceuticals figures

See a number that looks wrong?